Mobius (Memantine Hydrochloride)

Memantine, the active ingredient in Mobius, is an NMDA receptor antagonist presented as an oral tablet for oral use. It is indicated for the treatment of Alzheimer's disease in adult patients, helping to reduce excitotoxic neuronal damage and support cognitive function.

GNH USA supplies Mobius as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Customers benefit from consistent product availability and regulatory compliance across EU and other markets.

Memantine acts on the glutamatergic pathway and is approved for specific types of dementia.

Alzheimer's disease (moderate to severe): improves cognition, daily functioning, and global clinical status. Alzheimer's disease (mild to moderate): used as adjunct therapy to support cognitive symptoms. Alzheimer's disease with behavioral disturbances: may reduce agitation and improve patient care.

Common Side Effects: - Dizziness - Headache - Constipation - Fatigue - Confusion - Hypertension

Serious or Rare Side Effects: - Seizures - Cardiac arrhythmias - Severe hypersensitivity reactions (e.g., Stevens‑Johnson syndrome) - Hepatic injury - Suicidal thoughts or behavior - Severe skin reactions such as toxic epidermal necrolysis

Memantine should be used with caution in the following situations: - Renal impairment: adjust dose and monitor renal function. - History of seizures: use with caution, monitor for seizure activity. - Cardiovascular disease: monitor blood pressure and heart rate. - Concurrent use with other NMDA antagonists: avoid combination. - Pregnancy and lactation: safety not established; weigh risks and benefits. - Store at ambient temperature: keep in original container, protect from moisture and light.

Memantine may interact with several medicines. Review the following interactions before prescribing:

Major Interactions (Avoid): - Amantadine: additive NMDA antagonism may increase toxicity. - Ketamine: combined NMDA blockade may cause severe CNS effects. - High‑dose anticholinergics: may reduce therapeutic benefit.

Moderate Interactions (Monitor Closely): - CNS depressants (e.g., benzodiazepines): may enhance sedation. - Diuretics (e.g., furosemide): may increase risk of hypotension. - Antihypertensives: monitor blood pressure.